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Question: Does injection of Botulinum toxin followed by 
constraint-induced movement therapy improve spasticity 
and upper limb motor function more than the same injection 
followed by rehabilitation based on neurodevelopmental 
techniques? Design: Randomised trial with concealed 
allocation and blinded outcome assessment. Setting: 
Rehabilitation department of a tertiary hospital in Taiwan. 
Participants: Adults at least one year after a stroke with a 
Modified Ashworth Scale (MAS) score of 3 or more in the 
elbow, wrist, or finger flexors, and with at least 10 degrees of 
active interphalangeal and metacarpophalangeal extension 
and 20 degrees of wrist extension. Fixed contractures, 
major co-morbidities, and previous Botulinum toxin 
injection or surgery for spasticity were exclusion criteria. 
Randomisation of 32 participants allotted 16 to each group. 
Interventions: Both groups received a total dose of 1000 
units of Botulinum toxin type A, injected at standard 
muscular sites in the affected upper limb, and commenced 
their 3-month rehabilitation regimen the following day. 
The intervention group underwent intensive training of the 
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Synopsis
affected upper limb for 2 hours, 3 times per week, while the 
non-affected upper limb was restrained for at least 5 hours 
per day. Selected tasks were progressed in complexity, with 
some assistance with movements and verbal feedback and 
encouragement. The control group received 1 hour each of 
physiotherapy and occupational therapy, 3 times per week. 
Therapy was based on neurodevelopmental techniques, 
focusing on normalising tone, and movement patterns. 
Outcome measures: The primary outcome was the MAS (0 
= no spasticity, 4 = rigid in flexion or extension). Secondary 
outcomes included the Motor Activity Log (MAL), 
comprising two 6-point scales of amount of use and quality 
of movement, and the Action Research Arm Test (ARAT), 
which rates 19 tasks from 0 (no movement possible) to 3 
(normal movement), to give a total score out of 57. Results: 
29 participants completed the study. At 6 months, the 
treatment group had significantly greater reduction in MAS 
scores for the elbow (0.7, 95% CI 0.1 to 1.3), wrist (0.7, 
95% CI 0.2 to 1.2), and fingers (1.2, 95% CI 0.9 to 1.5). 
Also at 6 months, the treatment group had significantly 
greater improvement in amount of use (1.1, 95% CI 0.8 
to 1.4), quality of movement (0.9, 95% CI 0.6 to 1.2), and 
ARAT scores (7, 95% CI 4 to 10). Conclusion: Injection of 
Botulinum toxin followed by constraint-induced movement 
therapy improves spasticity and upper limb motor function 
more than the same injection followed by rehabilitation 
based on neurodevelopmental techniques.
[95% CIs calculated by the CAP Editor.]
Commentary
This paper presents convincing evidence of the efficacy 
of combining Botulinum toxin type A injections with 
modified constraint-induced movement therapy in reducing 
spasticity and improving arm and hand function in patients 
with spasticity more than one year after stroke. The results 
are impressive, since the most consistent between-group 
differences occurred 6 months post-injection and 3 months 
post-training, suggesting that participants had ongoing 
gains even when the effect of the injections would be 
expected to have worn off. This strengthens the evidence 
that the benefits of constraint-induced movement therapy 
persist beyond the period of therapy (Kwakkel et al 2007), 
especially since some of these data were uncontrolled 
(Askim and Indredavik 2008).
There are a number of challenges to be addressed in 
implementing this intervention in clinical practice. First, 
evaluation of potential patients should include assessment 
of spasticity and active movement. The combined protocol 
was effective for a group of patients who had moderate 
to severe spasticity in the elbow, wrist and/or finger 
flexors, as well as enough strength to be able to produce 
10 degrees of active extension of the interphalangeal and 
metacarpophalangeal joints and 20 degrees of active wrist 
extension. The absence of either of these criteria should 
suggest an alternate intervention. For example, modified 
constraint-induced movement therapy alone is effective 
in patients without spasticity (Langhorne et al 2009), so 
in these cases the use of Botulinum toxin injections is not 
recommended. In patients with significant weakness, the 
use of mental practice has shown promising results as a 
precursor to implementing modified constraint-induced 
movement therapy (Page et al 2007).
The second major challenge is the feasibility of providing 
one-on-one supervised practice for 3 2-hour sessions per 
week over 3 months, ie, a total of 72 hrs of supervised 
outpatient physiotherapy. The expense of travel to and from 
the facility is a further obstacle to implementation (Wolf 
et al 2007). It is unlikely that this amount of therapy could 
be funded in many circumstances. Physiotherapists are 
therefore challenged to deliver modified constraint-induced 
movement therapy by incorporating group and/or home-
based practice (English et al 2008, Williams et al 2009).
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